Resveratrol-loaded polymeric nanoparticles suppress glucose metabolism and tumor growth in vitro and in vivo

International Journal of Pharmaceutics

Volumn 478, Issue 1, 2015, Pages 251-257

  Jung, Kyung Ho ^a,b   Lee, Jin Hee ^a   Park, Jin Won ^a   Quach, Cung Hoa Thien ^a   Moon, Seung Hwan ^a   Cho, Young Seok ^a   Lee, Kyung Han ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Anticancer effect; Glucose metabolism; PEG PLA; Resveratrol

Indexed keywords

CASPASE 3; FLUORODEOXYGLUCOSE F 18; MACROGOL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYLACTIC ACID; REACTIVE OXYGEN METABOLITE; RESVERATROL; ANTINEOPLASTIC AGENT; GLUCOSE; MACROGOL DERIVATIVE; MONOMETHOXYPOLYETHYLENEGLYCOL-POLYLACTIDE BLOCK COPOLYMER; NANOPARTICLE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL COUNT; CELL SURVIVAL; COLONY FORMING UNIT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STABILITY; FLOW CYTOMETRY; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; SLOW DRUG RELEASE; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; DRUG RELEASE; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; DRUG LIBERATION; GLUCOSE; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; POLYETHYLENE GLYCOLS; REACTIVE OXYGEN SPECIES; STILBENES; TUMOR BURDEN;

EID: 84913583135     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.11.049     Document Type: Article

References (27)

1. Adams, M.L., Lavasanifar, A., Kwon, G.S., 2003. Amphiphilic block copolymers for drug delivery. J. Pharm. Sci. 92, 1343-1355.
2. Alkhalaf, M., 2007. Resveratrol-induced apoptosis is associated with activation of p53 and inhibition of protein translation in T47D human breast cancer cells. Pharmacology 80, 134-143.
3. Amri, A., Chaumeil, J.C., Sfar, S., Charrueau, C., 2012. Administration of resveratrol: What formulation solutions to bioavailability limitations? J. Control Release 158, 182-193.
4. Asensi, M., Medina, I., Ortega, A., Carretero, J., Baño, M.C., Obrador, E., Estrela, J.M., 2002. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. 33, 387-398.
5. Baur, J.A., Sinclair, D.A., 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5, 493-506.
6. Busquets, S., Ametller, E., Fuster, G., Olivan, M., Raab, V., Argilés, J.M., López-Soriano, F.J., 2007. Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett. 245, 144-148.
7. Cao, Z., Fang, J., Xia, C., Shi, X., Jiang, B.H., 2004. trans-3,4,5′-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin. Cancer Res. 10, 5253-5263.
8. Coimbra, M., Isacchi, B., van Bloois, L., Torano, J.S., Ket, A., Wu, X., Broere, F., Metselaar, J.M., Rijcken, C.J., Storm, G., Bilia, R., Schiffelers, R.M., 2011. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int. J. Pharm. 416, 433-442.
9. Euhus, D.M., Hudd, C., LaRegina, M.C., Johnson, F.E., 1986. Tumor measurement in the nude mouse. J. Surg. Oncol. 31, 229-234.
10. Galvao, J., Davis, B., Tilley, M., Normando, E., Duchen, M.R., Cordeiro, M.F., 2014. Unexpected low-dose toxicity of the universal solvent DMSO. FASEB J. 28, 1317-1330.
11. Guo, L., Peng, Y., Yao, J., Sui, L., Gu, A., Wang, J., 2010. Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice. Cancer Biother. Radiopharm. 25, 471-477.
12. Jang, M., Cai, L., Udeani, G.O., Slowing, K.V., Thomas, C.F., Beecher, C.W., Fong, H.H., Farnsworth, N.R., Kinghorn, A.D., Mehta, R.G., Moon, R.C., Pezzuto, J.M., 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220.
13. Jung, K.H., Lee, J.H., Thien Quach, C.H., Paik, J.Y., Oh, H., Park, J.W., Lee, E.J., Moon, S.H., Lee, K.H., 2013. Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1α activation. J. Nucl. Med. 54, 2161-2167.
14. Kotha, A., Sekharam, M., Cilenti, L., Siddiquee, K., Khaled, A., Zervos, A.S., Carter, B., Turkson, J., Jove, R., 2006. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther. 5, 621-629.
15. Li, Y., Qi, X.R., Maitani, Y., Nagai, T., 2009. PEG-PLA diblock copolymer micelle-like nanoparticles as all-trans-retinoic acid carrier: in vitro and in vivo characterizations. Nanotechnology 20, 55,106.
16. Lu, X., Ji, C., Xu, H., Li, X., Ding, H., Ye, M., Zhu, Z., Ding, D., Jiang, X., Ding, X., Guo, X., 2009. Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress. Int. J. Pharm. 375, 89-96.
17. Maeda, H., 2012. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J. Control Release 164, 138-144.
18. Mahapatro, A., Singh, D.K., 2011. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J. Nanobiotechnol. 9, 55.
19. Marier, J.F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J.P., Ducharme, M.P., 2002. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohpatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther. 302, 369-373.
20. Neves, A.R., Lúcio, M., Martins, S., Lima, J.L., Reis, S., 2013. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int. J. Nanomed. 8, 177-187.
21. Sanna, V., Roggio, A.M., Siliani, S., Piccinini, M., Marceddu, S., Mariani, A., Sechi, M., 2012. Development of novel cationic chitosan- and anionic alginate-coated poly (D,L-lactide-co-glycolide) nanoparticles for controlled release and light protection of resveratrol. Int. J. Nanomed. 7, 5501-5516.
22. Schädlich, A., Caysa, H., Mueller, T., Tenambergen, F., Rose, C., Göpferich, A., Kuntsche, J., Mäder, K., 2011. Tumor accumulation of NIR fluorescent PEG-PLA nanoparticles: impact of particle size and human xenograft tumor model. ACS Nano 5, 8710-8720.
23. Shao, J., Li, X., Lu, X., Jiang, C., Hu, Y., Li, Q., You, Y., Fu, Z., 2009. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf. B 72, 40-47.
24. Shukla, Y., Singh, R., 2011. Resveratrol and cellular mechanisms of cancer prevention. Ann. N. Y. Acad. Sci. 1215, 1-8.
25. Walle, T., Hsieh, F., DeLegge, M.H., Oatis Jr., J.E., Walle, U.K., 2004. High absorption but very low bioavailability of oral resveratrol metabolism in humans. Drug Metab. Dispos. 32, 1377-1382.
26. Wenzel, E., Somoza, V., 2005. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 49, 472-481.
27. Zhang, Q., Tang, X., Lu, Q.Y., Zhang, Z.F., Brown, J., Le, A.D., 2005. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol. Cancer Ther. 4, 1465-1474.